Recent advances in 1,2,4-triazole chemistry and its biological role in the development of anticancer targets through the inhibition of EGFR, VEGFR-2 and different carbonic anhydrase enzymes are presented.
Abstract
1,2,4-Triazoles have been interesting in the field of heterocyclic chemistry and their utility has been expanded to biological areas including cancer therapy, drug research and development. Thus, this review focuses on the synthetic aspects and biological role played by 1,2,4-triazoles in anticancer treatment and research. Epidermal growth factor receptors (EGFRs), vascular endothelial growth factor-2 (VEGFR-2) and carbonic anhydrases are important classes of oncogenic targets that have attracted significant attention because of their role in cancer studies. By inhibiting these target-specific enzymes it is possible to treat various types of cancer for which 1,2,4-triazoles have shown tremendous progress in development as anticancer agents. Therefore, this review presents recent advances in 1,2,4-triazole chemistry and its biological role in the development of anticancer targets through the inhibition of EGFR, VEGFR-2 and different carbonic anhydrase enzymes. Synthetic aspects help us understand the importance of molecular generation in drug design and discovery. Anticancer studies are helpful for determining the types of active targets among the class of 1,2,4-triazoles. Molecular docking studies reveal major interactions with several amino acid residues and furnish better comparisons with standard reference drugs. A structure–activity relationship (SAR) study enables us to determine the role played by the substituents linked to 1,2,4-triazole hybrids. Herein, we discuss the latest advances in the identification of 1,2,4-triazole-based anticancer targets and active compounds, with the exclusive literature covering the last six years.
This review compiles in vitro, in vivo, and in silico data on triazole‐ and imidazole‐based VEGFR‐2 inhibitors, providing a basis for understanding trends relevant to the design and development of optimized anti‐angiogenic agents.
Parisa Nikfar, Mina Hosseini, Nima Rezaei et al.· Archiv der Pharmazie· 0 citations
This review outlines synthetic strategies for N-((5-phenyl-1H-pyrazol-3-yl) carbamothioyl) benzamide derivatives, evaluates their biological activity, and discusses structure–activity relationships (SAR).
A. Hamza, Mohammed Shakir Ali, Hasan I. Sultani et al.· Genetics and Molecular Resea...· 0 citations
This review is an attempt to bridge the gap between synthetic structural biology and translational oncology by systematically connecting the structure- activity relationships of novel triazole hybrids targeting Aromatase, VEGFR-2, IDO1, and Carbonic Anhydrase.
Yashika Jangra, S. Dev, P. Jain· Mini-Reviews in Medical Chem...· 0 citations
A novel series of benzofuran-based aryl urea derivatives incorporating a 1,3,4-thiadiazole linker were designed as dual VEGFR-2/BRAFWT inhibitors using sorafenib as a pharmacophoric template, with compound 7j emerging as the most active analogue.
Marwa I. Serag, Mohamed R. Elnagar, Wafaa A. Ewes et al.· Bioorganic & Medicinal Chemi...· 1 citation
A new series of quinoline-diphenylpyrazole hybrids were rationally designed, synthesized, and biologically evaluated as potential EGFR/VEGFR-2/COX-2 inhibitors, supporting the proposed hybrid design strategy.
Abdelrahman Hamdi, Mohamed R. Elnagar, M. Hussein et al.· Bioorganic chemistry (Print)· 0 citations
Vascular endothelial growth factor receptor-2 (VEGFR-2) is a vital mediator of angiogenesis. Therefore, VEGFR-2 inhibition is considered a promising therapeutic target to combat cancer. In the present study, a series of 22 imidazo[4,5-b]pyridine-acrylonitrile-based derivatives was designed and synthesized. All compound...
Lamia W. Mohamed, Ahmed A. Saadeldin, Ayman B. Farag· Drug development research (P...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.